Ventabren Holdings

Ventyx Biosciences is a clinical-stage biopharmaceutical company dedicated to developing a pipeline of innovative small molecule therapies for inflammatory and autoimmune diseases. The company was formed through the strategic consolidation of three specialized biotechs—Ventyx, Oppilan Pharma, and Zomagen Biosciences—under a unified leadership team with deep expertise in immunology. Its portfolio targets well-validated pathways, including TYK2, S1P1, and NLRP3, with the goal of creating best-in-class oral treatments that can serve as alternatives to injectable biologics. Key programs include VTX002, an S1P1 receptor modulator for ulcerative colitis, and VTX3232, a CNS-penetrant NLRP3 inhibitor being explored for neuroinflammatory and metabolic conditions. Headquartered in San Diego, Ventyx aims to address significant unmet needs in the multi-billion dollar immunology market.